Cyclosporin A--a review on fermentative production, downstream processing and pharmacological applications.
Shrikant A Survase, Lalit D Kagliwal, Uday S Annapure...
https://pubmed.ncbi.nlm.nih.gov/21447377/Actively Recruiting
Led by University of California, San Francisco · Updated on 2026-06-05
150
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating whether adding topical Cyclosporine A eye drops to standard treatment with Natamycin improves vision outcomes in patients with fungal keratitis, an infection of the cornea. This randomized, masked clinical trial compares low-dose 0.1% and higher-dose 2% Cyclosporine A against a placebo to see which works best as an additional therapy. The study aims to find out if early use of Cyclosporine A benefits mild to moderate fungal keratitis and which ulcer features predict the most improvement. Participants with confirmed fungal keratitis receive topical Natamycin drops for at least 48 hours. Then they are randomly assigned to one of three groups Cyclosporine A 0.1%, Cyclosporine A 2%, or placebo for four weeks. Natamycin treatment continues until the corneal ulcer has healed. The drops are used four times a day for one month, then twice daily for another month. This trial is conducted with cornea specialists at a hospital where fungal keratitis is common. Participants will have their best corrected vision tested at 12 weeks as the primary outcome. Other assessments include measuring corneal scar size, checking for corneal perforation, tracking ulcer healing, and confirming microbiologic cure. The study involves regular follow-ups to monitor healing and safety. Overall participation spans about three months, during which vision and eye health are carefully evaluated to understand the effects of the treatments.
CONDITIONS
Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
G
Gerami D Seitzman, MD
T
Thomas Lietman, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Francisco
Lead Sponsor
Aravind Eye Hospitals, India
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Cyclosporine A 0.1% (with natamycin) | Cyclosporine A 2% (with natamycin) | Placebo (with natamycin) |
|---|---|---|---|
| What it is | Topical cyclosporine A 0.1% eye drops added to natamycin, an antifungal medication, for the treatment of fungal keratitis. | Topical cyclosporine A 2% eye drops combined with natamycin, used for treating proven fungal keratitis. | Topical placebo eye drops (matching cyclosporine formulation without active drug) combined with continued natamycin for fungal keratitis. |
| Role in trial | Test arm receiving Cyclosporine A 0.1% to evaluate whether adding an immune-modulating agent improves outcomes when combined with standard natamycin. | Test arm receiving a higher dose of Cyclosporine A (2%) to explore dose-dependent effects when used in addition to natamycin. | Control arm to assess outcomes with natamycin plus placebo, reflecting treatment without additional cyclosporine. |
| Primary use | To determine whether topical Cyclosporine A 0.1% added to natamycin improves vision and corneal healing in adults with fungal keratitis. | To investigate potential improvement in vision and healing when topical Cyclosporine A 2% is combined with natamycin in treating fungal keratitis. | To serve as a control group to assess the effect of natamycin alone on visual acuity and corneal healing, with placebo instead of cyclosporine A. |
| How it is given or performed | Participants receive at least 48 hours of topical natamycin before being randomized to cyclosporine A 0.1% or placebo, continued for 4 weeks as eye drops. Natamycin is continued until the ulcer heals. | Same as the other arms: after at least 48 hours of initial natamycin, participants receive cyclosporine A 2% as eye drops for 4 weeks, with ongoing natamycin until healing. | Placebo eye drops administered for 4 weeks after at least 48 hours of initial natamycin, with continued natamycin until corneal ulcer healing. |
| Evidence status | Cyclosporine A 0.1% is under active study in this randomized trial to determine its effect on visual outcomes and healing; results are not yet established. Existing published data primarily relate to use in transplantation or as adjunct therapy in related corneal conditions. | Cyclosporine A 2% use for fungal keratitis is under study in this trial. The current literature focuses mainly on lower concentrations, with higher-dose topical use less established. | Placebo recipients continue standard natamycin therapy; published clinical guidelines recognize natamycin as established first-line therapy for fungal keratitis. |
| Important limitations | Clinical benefit of adjunctive topical cyclosporine A 0.1% added to natamycin is not yet established; prior studies have not clearly demonstrated a risk-benefit profile in fungal keratitis outside transplant scenarios. | Efficacy and safety of high-dose (2%) topical cyclosporine A have not yet been determined for fungal keratitis; current evidence in the literature is limited for this concentration and indication. | While natamycin is widely used, some severe cases or certain fungal species may be less responsive, and adjunct therapies are still being studied. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At least 4 weeks of randomized treatment plus ongoing natamycin until healing
Participants are treated with topical natamycin for a minimum of 48 hours and then randomized to receive topical Cyclosporine A 0.1%, Cyclosporine A 2%, or placebo for 4 weeks. Natamycin treatment continues until the corneal ulcer has healed.
Weekly visits for up to 4 weeks during randomized treatment
Duration - Up to 12 weeks
Participants are monitored for outcomes including visual acuity, corneal healing, and complications up to 12 weeks after treatment starts.
1 to 2 visits depending on healing progress
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Shrikant A Survase, Lalit D Kagliwal, Uday S Annapure...
https://pubmed.ncbi.nlm.nih.gov/21447377/Henry D Perry, Sima J Doshi, Eric D Donnenfeld...
https://pubmed.ncbi.nlm.nih.gov/11862086/Samrat Chatterjee, Deepshikha Agrawal
https://pubmed.ncbi.nlm.nih.gov/34483271/N P Bell, C L Karp, E C Alfonso...
https://pubmed.ncbi.nlm.nih.gov/10336034/M Kauss Hornecker, S Charles Weber, M-L Brandely Piat...
https://pubmed.ncbi.nlm.nih.gov/26371985/Rossana de Aguiar Cordeiro, Ramila de Brito Macedo, Carlos Eduardo Cordeiro Teixeira...
https://pubmed.ncbi.nlm.nih.gov/24722799/University of California, San Francisco
Lead Sponsor
Aravind Eye Hospitals, India
Collaborating Sponsor